Nomura Holdings Inc. purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,533 shares of the biopharmaceutical company’s stock, valued at approximately $3,209,000.
Several other hedge funds have also added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. grew its position in shares of Regeneron Pharmaceuticals by 13.3% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 3,212 shares of the biopharmaceutical company’s stock valued at $1,578,000 after purchasing an additional 378 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Regeneron Pharmaceuticals by 1.2% in the second quarter. The Manufacturers Life Insurance Company now owns 84,977 shares of the biopharmaceutical company’s stock valued at $41,735,000 after purchasing an additional 1,037 shares during the last quarter. Cubist Systematic Strategies LLC grew its position in shares of Regeneron Pharmaceuticals by 176.1% in the second quarter. Cubist Systematic Strategies LLC now owns 671 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 428 shares during the last quarter. PointState Capital LP acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $78,199,000. Finally, Janus Henderson Group PLC grew its position in shares of Regeneron Pharmaceuticals by 15,495.4% in the second quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock valued at $767,637,000 after purchasing an additional 1,552,948 shares during the last quarter. Institutional investors and hedge funds own 67.41% of the company’s stock.
Several analysts have recently commented on REGN shares. Leerink Swann reiterated a “positive” rating and issued a $552.00 price target (down from $580.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 15th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $557.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 1st. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Jefferies Group LLC reiterated a “hold” rating and issued a $500.00 price target (up from $471.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, October 6th. Finally, Robert W. Baird reiterated a “sell” rating and issued a $408.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, September 8th. Three analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $489.92.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter in the prior year, the company posted $2.82 EPS. The business’s revenue was up 21.2% on a year-over-year basis. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.95 EPS for the current fiscal year.
In related news, major shareholder Sanofi acquired 166,415 shares of the firm’s stock in a transaction on Thursday, August 24th. The shares were purchased at an average price of $480.93 per share, with a total value of $80,033,965.95. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Robert E. Landry sold 189 shares of the stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the sale, the chief financial officer now directly owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. In the last 90 days, insiders sold 89,468 shares of company stock valued at $42,312,448. Corporate insiders own 10.80% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Nomura Holdings Inc. Takes $3.21 Million Position in Regeneron Pharmaceuticals, Inc. (REGN)” was published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2017/10/13/nomura-holdings-inc-takes-3-21-million-position-in-regeneron-pharmaceuticals-inc-regn.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
What are top analysts saying about Regeneron Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regeneron Pharmaceuticals Inc. and related companies.